Brief: Hikma Pharmaceuticals Tightens FY Core Operating Profit Range To $730 Million-$750 Million

Hikma Pharmaceuticals

06/11/2025 07:41

Nov 6 (Reuters) - Hikma Pharmaceuticals PLC HIK.L:

HIKMA PHARMACEUTICAL  - NOVEMBER TRADING STATEMENT

HIKMA - EXPECTS 2025 GROUP REVENUE GROWTH OF 4%-6%

HIKMA - TIGHTENS FY CORE OPERATING PROFIT RANGE TO $730M-$750M

HIKMA - NOW EXPECT OUR THREE-YEAR GROUP REVENUE CAGR (2024 TO 2027) OF 6% TO 8% TO BE AT LOWER END OF RANGE

HIKMA OUTLOOK MEDIUM-TERM GROUP CORE OPERATING PROFIT TO GROW IN RANGE OF 5% TO 7%

HIKMA: BILL LARKINS HAS STEPPED DOWN FROM HIS LEADERSHIP OF INJECTABLES BUSINESS

HIKMA: RIAD MISHLAWI, CEO, WILL ACT AS INTERIM HEAD OF INJECTABLES BUSINESS

Source text: ID:nRSF3878Ga

Further company coverage: HIK.L

 ((Reuters.Briefs@thomsonreuters.com;))